Literature DB >> 25759556

Protracted anaphylaxis developed after peginterferon α-2a administration for chronic hepatitis C.

Akihiko Sakatani1, Yoshinori Doi1, Takaaki Matsuda1, Yasutaka Sasai1, Naohiro Nishida1, Megumi Sakamoto1, Naoto Uenoyama1, Yoshiya Matsumoto1, Kazuo Kinoshita1.   

Abstract

Peginterferon is a key drug used to treat chronic viral hepatitis that is known for causing various side effects. Side effects occurring immediately after administration include headache, nausea, and influenza-like symptoms, such as fever and joint pain. However, reports of anaphylactic shock are extremely rare. Here we report a patient with protracted anaphylaxis who suffered shock symptoms after peginterferon α-2a administration for chronic hepatitis C. Although the patient improved temporarily with shock treatment, symptoms of anaphylaxis recurred. As peginterferon is often administered on an outpatient basis, it is important to recognize life-threatening side effects that may develop in a protracted manner.

Entities:  

Keywords:  Anaphylactic shock; Anaphylaxis; Chronic hepatitis C; Peginterferon α-2a; Protracted anaphylaxis

Mesh:

Substances:

Year:  2015        PMID: 25759556      PMCID: PMC4351238          DOI: 10.3748/wjg.v21.i9.2826

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  15 in total

Review 1.  Case report of anaphylaxis from cisplatin/paclitaxel and a review of their hypersensitivity reaction profiles.

Authors:  C Ciesielski-Carlucci; P Leong; C Jacobs
Journal:  Am J Clin Oncol       Date:  1997-08       Impact factor: 2.339

2.  Imaging-related medications: a class overview.

Authors:  Jill M Widmark
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-10

3.  Interferon beta 1a anaphylaxis, a case report. Standardization of non-irritating concentration for allergy skin tests.

Authors:  G Cortellini; A Amadori; T Comandini; A Corvetta
Journal:  Eur Ann Allergy Clin Immunol       Date:  2013-09-01

4.  Severe anaphylaxis with recombinant interferon beta.

Authors:  T Corona; C Leon; L Ostrosky-Zeichner
Journal:  Neurology       Date:  1999-01-15       Impact factor: 9.910

Review 5.  A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force.

Authors:  S G Johansson; J O Hourihane; J Bousquet; C Bruijnzeel-Koomen; S Dreborg; T Haahtela; M L Kowalski; N Mygind; J Ring; P van Cauwenberge; M van Hage-Hamsten; B Wüthrich
Journal:  Allergy       Date:  2001-09       Impact factor: 13.146

6.  Side effects of high-dose interferon therapy for chronic hepatitis C.

Authors:  T Okanoue; S Sakamoto; Y Itoh; M Minami; K Yasui; M Sakamoto; K Nishioji; T Katagishi; Y Nakagawa; H Tada; Y Sawa; M Mizuno; K Kagawa; K Kashima
Journal:  J Hepatol       Date:  1996-09       Impact factor: 25.083

Review 7.  Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

Authors:  Mark S Sulkowski; Curtis Cooper; Bela Hunyady; Jidong Jia; Pavel Ogurtsov; Markus Peck-Radosavljevic; Mitchell L Shiffman; Cihan Yurdaydin; Olav Dalgard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-08       Impact factor: 46.802

8.  Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis.

Authors:  Sangil Lee; Erik P Hess; David M Nestler; Venkatesh R Bellamkonda Athmaram; M Fernanda Bellolio; Wyatt W Decker; James T C Li; John B Hagan; Veena Manivannan; Samuel C Vukov; Ronna L Campbell
Journal:  J Allergy Clin Immunol       Date:  2013-02-27       Impact factor: 10.793

Review 9.  The post-anaphylaxis dilemma: how long is long enough to observe a patient after resolution of symptoms?

Authors:  Stephen F Kemp
Journal:  Curr Allergy Asthma Rep       Date:  2008-03       Impact factor: 4.806

Review 10.  Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma.

Authors:  Susan L Limb; Peter R Starke; Charles E Lee; Badrul A Chowdhury
Journal:  J Allergy Clin Immunol       Date:  2007-10-22       Impact factor: 10.793

View more
  4 in total

1.  Mast cell tryptase and carboxypeptidase A expression in body fluid and gastrointestinal tract associated with drug-related fatal anaphylaxis.

Authors:  Xiang-Jie Guo; Ying-Yuan Wang; Hao-Yue Zhang; Qian-Qian Jin; Cai-Rong Gao
Journal:  World J Gastroenterol       Date:  2015-12-21       Impact factor: 5.742

2.  Anti-PEG IgE in anaphylaxis associated with polyethylene glycol.

Authors:  Zhao-Hua Zhou; Cosby A Stone; Baruch Jakubovic; Elizabeth J Phillips; Gordon Sussman; JuMe Park; Uyen Hoang; Susan L Kirshner; Robert Levin; Steven Kozlowski
Journal:  J Allergy Clin Immunol Pract       Date:  2020-11-17

3.  Prolonged Anaphylaxis to Pfizer Coronavirus Disease 2019 Vaccine: A Case Report and Mechanism of Action.

Authors:  Ashleigh Frank; Sara Radparvar; Anthony Manasia; Adel Bassily-Marcus; Roopa Kohli-Seth
Journal:  Crit Care Explor       Date:  2021-04-02

4.  Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper.

Authors:  Aslı Gelincik; Knut Brockow; Gülfem E Çelik; Inmaculada Doña; Cristobalina Mayorga; Antonino Romano; Özge Soyer; Marina Atanaskovic-Markovic; Annick Barbaud; Maria Jose Torres
Journal:  Allergy       Date:  2020-07-01       Impact factor: 14.710

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.